Status:
COMPLETED
Enalapril After Anthracycline Cardiotoxicity
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Cardiovascular Diseases
Heart Diseases
Eligibility:
All Genders
1-17 years
Phase:
PHASE3
Brief Summary
To determine if the chronic administration of enalapril, an inhibitor of angiotensin converting enzyme (ACE), reduces progression of cardiac dysfunction in pediatric oncology patients who have receive...
Detailed Description
BACKGROUND: Pediatric oncology patients who have been treated with anthracycline therapy as a part of their chemotherapeutic regimen often subsequently develop left ventricular failure. The optimal m...
Eligibility Criteria
Boy and girl pediatric oncology patients, at least two years off treatment, with some cardiac dysfunction, but not congestive heart failure, after receiving anthracyclines. Patients were not on digoxin, diuretics, or vasodilators for heart failure.
Key Trial Info
Start Date :
April 1 1994
Trial Type :
INTERVENTIONAL
End Date :
February 1 2001
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000547
Start Date
April 1 1994
End Date
February 1 2001
Last Update
July 12 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.